Identical lesion morphology in primary progressive and relapsing-remitting MS - an ultrahigh field MRI study

被引：37

作者：

Kuchling, Joseph ^{[1
]}

Ramien, Caren ^{[1
]}

Bozin, Ivan ^{[1
]}

Doerr, Jan ^{[3
]}

Harms, Lutz ^{[4
]}

Rosche, Berit ^{[4
]}

Niendorf, Thoralf ^{[5
,6
]}

Paul, Friedemann ^{[1
,3
,6
]}

Sinnecker, Tim ^{[1
,2
]}

Wuerfel, Jens ^{[4
,6
,7
,8
]}

机构：

[1] Charite, NeuroCure Clin Res Ctr, D-10117 Berlin, Germany

[2] Asklepios Fachklinikum Teupitz, Teupitz, Germany

[3] Charite, NeuroCure Clin Res Ctr, Clin & Expt MS Res Ctr, D-10117 Berlin, Germany

[4] Charite, Clin & Expt MS Res Ctr, D-10117 Berlin, Germany

[5] Charite, BUFF, Expt & Clin Res Ctr, D-10117 Berlin, Germany

[6] Max Delbrueck Ctr Mol Med, Berlin, Germany

[7] Max Delbrueck Ctr Mol Med, NeuroCure Clin Res Ctr BUFF, Berlin, Germany

[8] Univ Med Goettingen, Inst Neuroradiol, Gottingen, Germany

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 14期

关键词：

MRI; primary progressive multiple sclerosis; PPMS; relapsing-remitting multiple sclerosis; RRMS; ultrahigh field MRI; 7 T MRI; MULTIPLE-SCLEROSIS; CORTICAL-LESIONS;

D O I：

10.1177/1352458514531084

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Potential differences between primary progressive (PP) and relapsing-remitting (RR) multiple sclerosis (MS) have been controversially discussed. In this study, we compared lesion morphology and distribution in patients with PPMS and RRMS (nine in each group) using 7 T MRI. We found that gray and white matter lesions in PPMS and RRMS patients did not differ in their respective morphological characteristics (e.g. perivascular p = 0.863, hypointense rim p = 0.796, cortical lesion count p = 0.436). Although limited by a small sample size, our study results suggest that PPMS and RRMS, despite differences in disease course and clinical characteristics, exhibit identical lesion morphology under ultrahigh field MRI.

引用

页码：1866 / 1871

页数：6

共 50 条

[31] Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary-progressive and relapsing-remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases [J].

Prajjwal, Priyadarshi ;

Marsool, Mohammed Dheyaa Marsool ;

Asharaf, Shahnaz ;

Inban, Pugazhendi ;

Gadam, Srikanth ;

Yadav, Rukesh ;

Vora, Neel ;

Nandwana, Varsha ;

Marsool, Ali Dheyaa Marsool ;

Amir, Omniat .

HEALTH SCIENCE REPORTS, 2023, 6 (07)

[32] Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis [J].

Esposito, Federica ;

Radaelli, Marta ;

Martinelli, Vittorio ;

Sormani, Maria Pia ;

Boneschi, Filippo Martinelli ;

Moiola, Lucia ;

Rocca, Maria Assunta ;

Rodegher, Mariaemma ;

Comi, Giancarlo .

MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (12) :1490-1499

[33] Clinical benefits of interferon beta-1a in relapsing-remitting MS:: a phase IV study [J].

Fernández, O ;

Arbizu, T ;

Izquierdo, G ;

Martínez-Yélamos, A ;

Gata, JM ;

Luque, G ;

de Ramón, E .

ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 (01) :7-11

[34] Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis [J].

Planche, V. ;

Gibelin, M. ;

Cregut, D. ;

Pereira, B. ;

Clavelou, P. .

EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 (02) :282-289

[35] Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis-A longitudinal MRI study [J].

Bendfeldt, Kerstin ;

Egger, Hanspeter ;

Nichols, Thomas E. ;

Loetscher, Patrick ;

Denier, Niklaus ;

Kuster, Pascal ;

Traud, Stefan ;

Mueller-Lenke, Nicole ;

Naegelin, Yvonne ;

Gass, Achim ;

Kappos, Ludwig ;

Radue, Ernst-Wilhelm ;

Borgwardt, Stefan J. .

BRAIN RESEARCH, 2010, 1325 :174-182

[36] Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity [J].

Hellings, N ;

Gelin, G ;

Medaer, R ;

Bruckers, L ;

Palmers, Y ;

Raus, J ;

Stinissen, P .

JOURNAL OF NEUROIMMUNOLOGY, 2002, 126 (1-2) :143-160

[37] MRI-based clinical trials in relapsing-remitting MS: new sample size calculations based on a longitudinal model [J].

Altman, R. M. ;

Petkau, A. J. ;

Vrecko, D. ;

Smith, A. .

MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (11) :1600-1608

[38] Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study [J].

Frau, Jessica ;

Sacca, Francesco ;

Signori, Alessio ;

Baroncini, Damiano ;

Fenu, Giuseppe ;

Annovazzi, Pietro ;

Capobianco, Marco ;

Signoriello, Elisabetta ;

Laroni, Alice ;

La Gioia, Sara ;

Sartori, Arianna ;

Maniscalco, Giorgia Teresa ;

Bonavita, Simona ;

Clerico, Marinella ;

Russo, Cinzia Valeria ;

Gallo, Antonio ;

Lapucci, Caterina ;

Carotenuto, Antonio ;

Sormani, Maria Pia ;

Cocco, Eleonora .

JOURNAL OF NEUROLOGY, 2019, 266 (10) :2440-2446

[39] Disconnection of the hippocampus and amygdala associated with lesion load in relapsing-remitting multiple sclerosis: a structural and functional connectivity study [J].

Zhou, Fuqing ;

Zhuang, Ying ;

Wang, Lingling ;

Zhang, Yue ;

Wu, Lin ;

Zeng, Xianjun ;

Gong, Honghan .

NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 :1749-1765

[40] Differentiation of relapsing-remitting and secondary progressive multiple sclerosis: a magnetic resonance spectroscopy study based on machine learning [J].

Eksi, Ziya ;

Cakiroglu, Murat ;

Oz, Cemil ;

Aralasmak, Ayse ;

Karadeli, Hasan Huseyin ;

Ozcan, Muhammed Emin .

ARQUIVOS DE NEURO-PSIQUIATRIA, 2020, 78 (12) :789-796

← 1 2 3 4 5 →